黄家宇,陈俊,刘兰,张敏,万立,李莉
HUANG Jiayu,CHEN Jun,LIU Lan,ZHANG Min,WANG Li,LI Li

• 1:贵州医科大学药学院

摘要(Abstract)：

目的:研究腺苷蛋氨酸(SAMe)配伍美洛昔康(MLX)肠溶制剂的处方配比和制备工艺。方法:拟定9种处方成分,以流动性、成型性、粒径分布以及临界相对湿度(CRH)为指标,筛选优化复方制剂的最佳制备工艺。结果:处方2为复方肠溶制剂制备的最佳处方,以5%乙醇制软材,24目尼龙筛制粒并整粒,添加0. 3%的微粉硅胶助流,装入0号肠溶空心胶囊中,即得SAMe配伍MLX复方肠溶胶囊剂;该复方颗粒的流动性好、粒径分布均匀(355~850μm)、成型性好(97. 44%)、CHR为78. 5%。结论:选择处方2所得复发颗粒有良好的流动性和成型性、制备工艺简单可行、合理有效,适用于SAMe配伍MLX复方肠溶胶囊的制备。
Objective: To study the optimization on formulation and process of compound enteric coated capsule consisting of S-adenosy-L-methionine and Meloxicam. Methods: Designing 9 kinds of formulation for compound enteric coated capsule with compound particle movement,shape,particle size distribution and critical relative humidity( CRH) as the index to determine the preparation process of compound enteric coated capsules. Results: The second formulation was the best one for the preparation of compound enteric coated capsule. The soft material was made with 5% ethanol,the granule was made with 24-mesh nylon screen and the whole granule was added with 0. 3% micropowder silica gel to assist the flow,and then put into No. 0 enteric dissolving hollow capsule,and the SAMe compatible with MLX compound enteric dissolving capsule was obtained. The compound particles had good fluidity,uniform size distribution( 355 ~ 850 μm),good shaping( 97. 44%) and CHR was 78. 5%.Conclusion: The recurrent granule obtained from formulation 2 has good fluidity and formability,the preparation process is simple and feasible,reasonable and effective,and is suitable for the preparation of the SAMe compatible with MLX compound enteric capsule.

关键词(KeyWords)： S-腺苷蛋氨酸;美洛昔康;骨关节炎;分析样品制备方法;药物制剂
S-adenosy-L-methionine;meloxicam;osteoarthritis;analytic sample preparation methods;compound preparation

Abstract:

Keywords:

基金项目(Foundation): 贵州省科技厅中药现代化专项项目[黔科合中药字(2013)5025号];; 2015年贵州省教育厅大学生创新创业项目(20151066000S)

作者(Author): 黄家宇,陈俊,刘兰,张敏,万立,李莉
HUANG Jiayu,CHEN Jun,LIU Lan,ZHANG Min,WANG Li,LI Li

DOI: 10.19367/j.cnki.1000-2707.2018.09.003

参考文献(References)：

• [1]张小军,习勇,封鹏,等.脂代谢指标对髋骨关节炎的影响因素分析[J].中华风湿病学杂志,2017,21(2):114-117.
• [2]HELMICK C G,FELSON D T,LAWRENCE R C,et al.Estimates of the prevalence of arthritis and other rheumatic conditions in the United States:part II[J]. Arthritis and Rheumatology,2008,58(10):26-35.
• [3]NEOGI T,ZHANG Y. Osteoarthritis prevention[J].Current Opinion in Rheumatology,2011,23(4):185-191.
• [4]AIGNER T,SACHSE A,GEBHARD P M,et al. Osteoarthritis:pathobiology-targets and ways for therapeutic intervention[J]. Advanced Drug Delivery Reviews,2006,58(2):128-149
• [5]LEE R,KEAN W F. Obesity and knee osteoarthritis[J].Inflammop Harmacology,2012,20(2):53-58.
• [6]NEOGI T,ZHANG Y. osteoarthritis prevention[J]. Current Opinion in Rheumatology,2011,23(8):185-191.
• [7]LIU P,OKUN A,REN J,et al. Ongoing pain in the MIA model of osteoarthritis[J]. Neurosci Lett,2011,493(3):72-75.
• [8]王芳侠,陈赞民. HPLC法测定1,4-丁二磺酸腺苷蛋氨酸肠溶片含量[J].中国热带医学,2007,7(8):1433-1433,1448.
• [9]魏芳,马焕云. S-腺苷蛋氨酸的研究进展及其临床应用[J].医学研究与教育,2009,26(1):81-82.
• [10]李昱江,诸葛,宇征. S-腺苷蛋氨酸在肝脏疾病发生发展中作用的研究进展[J].东南大学学报:医学版,2012,31(5):661-664.
• [11]肖晓山.骨性关节炎所致疼痛的治疗现状与展望[J].广东医学,2006(1):1-3.
• [12]李健和,胡焰,易利丹,等.美洛昔康制剂的研究开发及临床应用进展[J].中国药房,2013,24(2):162-167.
• [13]张敏,李莉,黄家宇,等.腺苷蛋氨酸配伍美洛昔康治疗膝骨关节炎的实验研究[J].中国新药杂志,2015,24(18):2142-2146,2152.
• [14]ATTUR MG,DAVE M,CIPOLLET TA,et al. Reversal of autocrine and paracrine effects of interleukin 1(IL-1)in human arthritis by type II IL-1 decoy receptor-Potential for pharmacological intervention[J]. Journal of Biological Chemistry,2000,275(51):40307-40315.
• [15]张敏.一种治疗骨性关节炎的复方制剂的研究与开发[D].贵阳:贵州医科大学,2016.
• [16]伍胤杰,李传印,张光贤,等.肠道病毒71型灭活疫苗生产中氢氧化铝佐剂制备工艺优化[J].贵州医科大学学报,2017,42(9):1022-1027.
• [17]吴朝花,姜丰,苏菊,等.氧化苦参碱微球体外累积释放百分率的影响因素[J].贵州医科大学学报,2017,42(6):674-678.

文章评论(Comment)：